

By: Senator(s) Turner-Ford, Blackwell,
Simmons (13th), McLendon

To: Drug Policy; Judiciary,
Division B

COMMITTEE SUBSTITUTE
FOR
SENATE BILL NO. 2355

1 AN ACT TO AMEND SECTION 41-29-117, MISSISSIPPI CODE OF 1972,
2 TO ADD ANY CHEMICALLY SYNTHESIZED COMPOUND, MIXTURE, OR
3 PREPARATION OF KRATOM TO SCHEDULE III OF THE UNIFORM CONTROLLED
4 SUBSTANCES ACT; AND FOR RELATED PURPOSES.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

6 **SECTION 1.** Section 41-29-117, Mississippi Code of 1972, is
7 amended as follows:

8 41-29-117. (A) The controlled substances listed in this
9 section are included in Schedule III.

10 **SCHEDULE III**

11 (a) **Stimulants.** Any material, compound, mixture, or
12 preparation which contains any quantity of the following
13 substances or their salts, isomers, or salts of isomers, of the
14 following substances:

- 15 (1) Benzphetamine;
16 (2) Chlorphentermine;
17 (3) Clortermine;
18 (4) Phendimetrazine.



19 (b) **Depressants.** Unless listed in another schedule,
20 any material, compound, mixture, or preparation which contains any
21 quantity of the following substances:

22 (1) Any substance which contains any quantity of a
23 derivative of barbituric acid, or any salt of a derivative of
24 barbituric acid, except those substances which are specifically
25 listed in other schedules;

26 (2) Unless specifically excepted or unless listed
27 in another schedule, any compound, mixture or preparation
28 containing any of the following substances or any salt of the
29 substances specifically included in this subsection (2) and one or
30 more other active medicinal ingredients which are not listed in
31 any other schedule:

32 (i) Amobarbital;

33 (ii) Secobarbital;

34 (iii) Pentobarbital;

35 (3) Any suppository dosage form containing any of
36 the following substances or any salt of any of the substances
37 specifically included in this subsection (3) approved by the Food
38 and Drug Administration for marketing only as a suppository:

39 (i) Amobarbital;

40 (ii) Secobarbital;

41 (iii) Pentobarbital;

42 (4) Chlorhexadol;

43 (5) Embutramide;



44 (6) Any drug product containing
45 gamma-hydroxybutyric acid, including its salts, isomers and salts
46 of isomers, for which an application is approved under Section 505
47 of the Federal Food, Drug and Cosmetic Act;

48 (7) Ketamine; its salts, isomers, and salts of
49 isomers; other names include

50 (+)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone;

51 (8) Lysergic acid;

52 (9) Lysergic acid amide;

53 (10) Methyprylon;

54 (11) Perampanel; its salts, isomers, and salts of
55 isomers;

56 (12) Sulfondiethylmethane;

57 (13) Sulfonethylmethane;

58 (14) Sulfonmethane;

59 (15) Tiletamine and zolazepam or any salt thereof;

60 other names for the tiletamine and zolazepam combination product
61 include: telazol; other names for tiletamine include:

62 2-(ethylamino)-2-(2-thienyl)-cyclohexanone; other names for

63 zolazepam include: 4-(2-fluorophenyl)-6,8-dihydro 1,3,

64 8-trimethylpyrazolo-[3,4-e](1,4)-diazepin-7(1H)-one, flupyrzapon.

65 (c) Nalorphine.

66 (d) Any material, compound, mixture or preparation
67 which contains any quantity of ephedrine or pseudoephedrine,
68 except for any product that contains any quantity of



pseudoephedrine or ephedrine that is sold subject to the quantity restrictions authorized in Section 73-21-124.

(e) **Narcotic drugs.** Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

(1) Not more than one and eight-tenths (1.8) grams of codeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) Not more than one and eight-tenths (1.8) grams of codeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) Not more than one and eight-tenths (1.8) grams of dihydrocodeine, or any of its salts, per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(4) Not more than three hundred (300) milligrams of ethylmorphine, or any of its salts, per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;



(5) Not more than five hundred (500) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams, or not more than twenty-five (25) milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) Not more than fifty (50) milligrams of morphine, or any of its salts, per one hundred (100) milliliters or per one hundred (100) grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(f) **Anabolic steroids.** Unless specifically exempted or listed in another schedule, any material, compound, mixture or preparation containing any quantity of any of the following anabolic steroids (any drug or hormonal substance chemically and pharmacologically related to testosterone other than estrogens, progestins, corticosteroids and dehydroepiandrosterone):

(1) 3beta,17-dihydroxy-5a-androstane;

(2) 3alpha,17beta-dihydroxy-5a-androstane;

(3) 5alpha-androstan-3,17-dione;

(4) 1-androstenediol
(3beta,17beta-dihydroxy-5alpha-androst-1-ene);

(5) 1-androstenediol
(3alpha,17beta-dihydroxy-5alpha-androst-1-ene);

(6) 4-androstenediol
(3beta,17beta-dihydroxy-androst-4-ene);



117 (7) 5-androstenediol
118 (3beta,17beta-dihydroxy-androst-5-ene);
119 (8) 1-androstenedione ([5alpha]-androst-1-en-3,
120 17-dione);
121 (9) 4-androstenedione (androst-4-en-3,17-dione);
122 (10) 5-androstenedione (androst-5-en-3,17-dione);
123 (11) Bolasterone
124 (7alpha,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
125 (12) Boldenone
126 (17beta-hydroxyandrost-1,4,-diene-3-one);
127 (13) Boldione (androsta-1,4-diene-3,17-dione);
128 (14) Calusterone
129 (7beta,17alpha-dimethyl-17beta-hydroxyandrost-4-en-3-one);
130 (15) Clostebol
131 (4-chloro-17beta-hydroxyandrost-4-en-3-one);
132 (16) Dehydrochloromethyltestosterone
133 (4-chloro-17beta-hydroxy-17alpha-methylandrost-1,4-dien-3-one);
134 (17) Desoxymethyltestosterone
135 (17alpha-methyl-5alpha-androst-2-en-17beta-ol, also known as
136 madol);
137 (18) Delta1-dihydrotestosterone (also known as
138 1-testosterone) (17beta-hydroxy-5alpha-androst-1-en-3-one);
139 (19) 4-dihydrotestosterone
140 (17beta-hydroxy-androstan-3-one);



141 (20) Drostanolone
 142 (17beta-hydroxy-2alpha-methyl-5alpha-androstan-3-one);
 143 (21) Ethylestrenol
 144 (17alpha-ethyl-17beta-hydroxyestr-4-ene);
 145 (22) Fluoxymesterone
 146 (9-fluoro-17alpha-methyl-11beta,
 147 17beta-dihydroxyandrost-4-en-3-one);
 148 (23) Formebolone
 149 (2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,
 150 4-dien-3-one);
 151 (24) Furazabol
 152 (17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan);
 153 (25) 13 beta-ethyl-17alpha-hydroxy on-4-en-3-one;
 154 (26) 4-hydroxy testosterone
 155 (4,17beta-dihydroxyandrost-4-en-3-one);
 156 (27) 4-hydroxy-19-nortestosterone
 157 (4,17beta-dihydroxy-estr-4-en-3-one);
 158 (28) Mestanolone
 159 (17alpha-methyl-17beta-hydroxy-5-androstan-3-one);
 160 (29) Metergoline
 161 (alpha-methyl-17beta-hydroxy-[5alpha]-androstan-3-one);
 162 (30) Methandienone
 163 (17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one);
 164 (31) Methandriol (17alpha-methyl-beta,
 165 17beta-dihydroxyandrost-5-ene);



166 (32) Metatron (2[alpha],
167 17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one;
168 (33) Methenolone
169 (1-methyl-17beta-hydroxy-5alpha-androst-1-en-3-one);
170 (34) 17alpha-methyl-beta,
171 17beta-dihydroxy-5a-androstane;
172 (35) 17alpha-methyl-alpha,
173 17beta-dihydroxy-5a-androstane;
174 (36) 17alpha-methyl-beta,
175 17beta-dihydroxyandrost-4-ene;
176 (37) 17alpha-methyl-4-hydroxy nandrolone
177 (17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one);
178 (38) Methyltrienolone
179 (17alpha-methyl-17beta-hydroxyester-4,9(10)-dien-3-one);
180 (39) Methyltrienolone
181 (17alpha-methyl-17beta-hydroxyester-4,9-11-triene-3-one);
182 (40) Methyltestosterone
183 (17alpha-methyl-17beta-hydroxyandrost-4-en-3-one);
184 (41) Mableton
185 (7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one);
186 (42) 17alpha-methyl-Delta1-dihydrotestosterone (17P
187 beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one) (also known
188 as 17-alpha-methyl-1-testosterone);
189 (43) Nandrolone (17beta-hydroxyestr-4-en-3-one);



190 (44) 19-nor-4-androstenediol
 191 (3beta,17beta-hydroxyester-4-ene);
 192 (45) 19-nor-4-androstenediol
 193 (Gambetta-hydroxyester-4-ene);
 194 (46) 19-nor-5-androstenediol
 195 (3beta,17beta-hydroxyester-5-ene);
 196 (47) 19-nor-5-androstenediol
 197 (3alpha,17beta-hydroxyester-5-ene);
 198 (48) 19-nor-4,9(10)-androstadiene Dione
 199 (estr-4,9(10)-diene-3,17-dione,
 200 19-norandrosta-4,9(10)-diene-3,17-dione);
 201 (49) 19-nor-4-androstenedione
 202 (estr-4-en-3,17-dione);
 203 (50) 19-nor-5-androstenedione
 204 (estr-5-en-3,17-dione);
 205 (51) Norbolethone
 206 (13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one);
 207 (52) Norclostebol
 208 (4-chloro-17beta-hydroxyestr-4-en-3-one);
 209 (53) Norethandrolone
 210 (17alpha-ethyl-17beta-hydroxyestr-4-en-3-one);
 211 (54) Normethandrolone
 212 (17alpha-methyl-17beta-hydroxyestr-4-en-3-one);
 213 (55) Oxandrolone
 214 (17alpha-methyl-17beta-hydroxy-2-oxa-[5alpha]-androstan-3-one);



215 (56) Oxymesterone
216 (17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one);
217 (57) Oxymetholone
218 (17alpha-methyl-2-hydroxymethylene-17beta-hydroxy-[5alpha]-
219 androstan-3-one);
220 (58) Prostanazol
221 (17[beta]-hydroxy-5[alpha]-androstan[3,2-c]pyrazole)
222 (59) Stanazolol
223 (17alpha-methyl-17beta-hydroxy-[5alpha]-androst-2-eno[3,2-c]-
224 pyrazole);
225 (60) Stenbolone
226 (17beta-hydroxy-2-methyl-[5alpha]-androst-1-en-3-one);
227 (61) Testolactone
228 (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
229 lactone);
230 (62) Testosterone
231 (17beta-hydroxyandrost-4-en-3-one);
232 (63) Tetrahydrogestrinone
233 (13beta,17alpha-diethyl-17beta-hydroxygon-4,9,11-trien-3-one);
234 (64) Trenbolone
235 (17beta-hydroxyestr-4,9,11-trien-3-one);
236 (65) Any salt, ester, or ether of a drug or
237 substance described in this paragraph. Except such term does not
238 include an anabolic steroid that is expressly intended for
239 administration through implants to cattle or other nonhuman



species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph.

(g) Any material, compound, mixture or preparation which contains any quantity of buprenorphine or its salts.

(h) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product.

(i) Any material, compound, mixture, or preparation which contains any quantity of Tianeptine (7-((3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino)heptanoic acid) or its salts, isomers, salts of isomers, sulfate, free acid or derivative thereof.

(j) Any chemically synthesized compound, mixture, or preparation which contains any quantity of mitragynine, commonly known as kratom, (7 hydroxymitragynine and/or 7-OH-mitragynine) in excess of one percent (1%) of the total alkaloid composition of the kratom product.

(B) Any material, compound, mixture or preparation which contains any quantity of a Schedule III controlled substance other than butalbital, and is listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 1308.26, 1308.32 or 1308.34, shall be



264 exempted from the provisions of the Uniform Controlled Substances
265 Law.

266 **SECTION 2.** This act shall take effect and be in force from
267 and after July 1, 2025, and shall stand repealed on June 30, 2025.

